Advances in Non-surgical Management of Primary Liver Cancer

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2014 Dec 4

PMID 25469032

Citations 30

Authors

Xiao Chen

Hai-Peng Liu

Mei Li

Liang Qiao

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third most common cause of cancer-related death worldwide. There have been great improvements in the diagnosis and treatment of HCC in recent years, but the problems, including difficult diagnosis at early stage, quick progression, and poor prognosis remain unsolved. Surgical resection is the mainstay of the treatment for HCC. However, 70%-80% of HCC patients are diagnosed at an advanced stage when most are ineligible for potentially curative therapies such as surgical resection and liver transplantation. In recent years, non-surgical management for unrespectable HCC, such as percutaneous ethanol injection, percutaneous microwave coagulation therapy, percutaneous radiofrequency ablation, transcatheter arterial chemoembolization, radiotherapy, chemotherapy, biotherapy, and hormonal therapy have been developed. These therapeutic options, either alone or in combination, have been shown to control tumor growth, prolong survival time, and improve quality of life to some extent. This review covers the current status and progress of non-surgical management for HCC.

Citing Articles

Tolerability and Effectiveness of Regorafenib Treatment in Patients with Unresectable Hepatocellular Carcinoma: Real-World Data from the United States.

Finn R, Iyer R, Kalman R, Parikh N, Cabrera R, Babajanyan S J Hepatocell Carcinoma. 2025; 12:231-246.

PMID: 39935697 PMC: 11812560. DOI: 10.2147/JHC.S459983.

Immunotherapy and liver cancer research trends and the 100 most cited articles: A bibliometric analysis.

Kong Y, Wang Y, Yang Q, Ye S Technol Health Care. 2024; 32(6):5141-5155.

PMID: 39093101 PMC: 11613086. DOI: 10.3233/THC-241111.

Glycyrrhetinic Acid Receptor-Mediated Zeolitic Imidazolate Framework-8 Loaded Doxorubicin as a Nanotherapeutic System for Liver Cancer Treatment.

Mi X, Lou Y, Wang Y, Dong M, Xue H, Li S Molecules. 2023; 28(24).

PMID: 38138618 PMC: 10745904. DOI: 10.3390/molecules28248131.

The progress of research on immune checkpoint inhibitor resistance and reversal strategies for hepatocellular carcinoma.

Kou L, Xie X, Chen X, Li B, Li J, Li Y Cancer Immunol Immunother. 2023; 72(12):3953-3969.

PMID: 37917364 PMC: 10992589. DOI: 10.1007/s00262-023-03568-3.

Trends in medical care utilization in patients with cancer: An analysis of real-world data in a tertiary hospital in Korea, 2014-2019.

Won J, Chung T, Lee J, Yoon S, Jeon Y, Lee H Cancer Med. 2023; 12(22):21022-21031.

PMID: 37902239 PMC: 10709731. DOI: 10.1002/cam4.6660.

References

Bruix J, Sherman M . Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53(3):1020-2. PMC: 3084991. DOI: 10.1002/hep.24199. View

Danila M, Sporea I, Sirli R, Popescu A . Percutaneous ethanol injection therapy in the treatment of hepatocarcinoma--results obtained from a series of 88 cases. J Gastrointestin Liver Dis. 2009; 18(3):317-22. View

Llovet J, Fuster J, Bruix J . The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 2004; 10(2 Suppl 1):S115-20. DOI: 10.1002/lt.20034. View

Khan K, Yatsuhashi H, Yamasaki K, Yamasaki M, Inoue O, Koga M . Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection. J Hepatol. 2000; 32(2):269-78. DOI: 10.1016/s0168-8278(00)80072-0. View

Llovet J, Bru C, Bruix J . Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999; 19(3):329-38. DOI: 10.1055/s-2007-1007122. View

Kerkar S, Carlin A, Sohn R, Steffes C, Tyburski J, Littrup P . Long-term follow up and prognostic factors for cryotherapy of malignant liver tumors. Surgery. 2004; 136(4):770-9. DOI: 10.1016/j.surg.2004.07.001. View

Dawson L, McGinn C, Normolle D, Ten Haken R, Walker S, Ensminger W . Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2000; 18(11):2210-8. DOI: 10.1200/JCO.2000.18.11.2210. View

Yang B, Zou J, Xia J, Ren Z, Gan Y, Wang Y . Risk factors for recurrence of small hepatocellular carcinoma after long-term follow-up of percutaneous radiofrequency ablation. Eur J Radiol. 2010; 79(2):196-200. DOI: 10.1016/j.ejrad.2010.02.010. View

Ramanathan R, Belani C, Singh D, Tanaka M, Lenz H, Yen Y . A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol. 2009; 64(4):777-83. DOI: 10.1007/s00280-009-0927-7. View

10.

Kim S, Imoto S, Nakajima T, Ando K, Mita K, Taniguchi M . Well-differentiated hepatocellular carcinoma smaller than 15 mm in diameter totally eradicated with percutaneous ethanol injection instead of radiofrequency ablation. Hepatol Int. 2009; 3(2):411-5. PMC: 2716769. DOI: 10.1007/s12072-009-9128-z. View

11.

Zeng Z, Jiang G, Wang G, Tang Z, Curran W, Iliakis G . DNA-PKcs subunits in radiosensitization by hyperthermia on hepatocellular carcinoma hepG2 cell line. World J Gastroenterol. 2002; 8(5):797-803. PMC: 4656564. DOI: 10.3748/wjg.v8.i5.797. View

12.

Cormier J, Thomas K, Chari R, Pinson C . Management of hepatocellular carcinoma. J Gastrointest Surg. 2006; 10(5):761-80. DOI: 10.1016/j.gassur.2005.10.006. View

13.

Orsi F, Zhang L, Arnone P, Orgera G, Bonomo G, Della Vigna P . High-intensity focused ultrasound ablation: effective and safe therapy for solid tumors in difficult locations. AJR Am J Roentgenol. 2010; 195(3):W245-52. DOI: 10.2214/AJR.09.3321. View

14.

Nowak A, Findlay M, Culjak G, Stockler M . Tamoxifen for hepatocellular carcinoma. Cochrane Database Syst Rev. 2004; (3):CD001024. DOI: 10.1002/14651858.CD001024.pub2. View

15.

Gish R, Porta C, Lazar L, Ruff P, Feld R, Croitoru A . Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol. 2007; 25(21):3069-75. DOI: 10.1200/JCO.2006.08.4046. View

16.

Nakagawa K, Yamashita H, Shiraishi K, Nakamura N, Tago M, Igaki H . Radiation therapy for portal venous invasion by hepatocellular carcinoma. World J Gastroenterol. 2006; 11(46):7237-41. PMC: 4725139. DOI: 10.3748/wjg.v11.i46.7237. View

17.

Parkin D, Bray F, Ferlay J, Pisani P . Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55(2):74-108. DOI: 10.3322/canjclin.55.2.74. View

18.

Bertelli R, Neri F, Tsivian M, Ruhrman N, Cavallari G, Beltempo P . Endolymphatic immunotherapy in inoperable hepatocellular carcinoma. Transplant Proc. 2008; 40(6):1913-5. DOI: 10.1016/j.transproceed.2008.05.049. View

19.

van Malenstein H, Dekervel J, Verslype C, Van Cutsem E, Windmolders P, Nevens F . Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth. Cancer Lett. 2012; 329(1):74-83. DOI: 10.1016/j.canlet.2012.10.021. View

20.

Yin X, Lu M . Percutaneous ablation for small hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2009; 3(2):121-30. DOI: 10.1586/egh.09.7. View